^
Association details:
| Biomarker: | MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement |
|---|---|
| Cancer: | Lymphoma |
| Drug: | Breyanzi (lisocabtagene maraleucel) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Excerpt:
...DLBCL cohort (no longer enrolling): DLBCL, not otherwise specified (NOS; includes transformed DLBCL from indolent histology [tDLBCL]), high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology...
Trial ID:
Source:
Title:
Safety and efficacy results from TRANSCEND NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory large B-cell lymphoma
Published date:
01/05/2021
Excerpt:
All primary and secondary efficacy endpoints were met. Of 256 efficacy‐evaluable patients, the ORR was 73% (95% confidence interval [CI], 67–78) and the CR rate was 53% (95% CI, 47–59)….high‐grade B‐cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements...Liso‐cel showed durable clinical activity with a favorable safety profile across relapsed/refractory LBCL histologic subgroups and in patients...
Trial ID:
Source:
Title:
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Published date:
09/01/2020
Excerpt:
...Eligible histological subgroups included diffuse large B-cell lymphoma, high-grade B-cell lymphoma with rearrangements of MYC and either BCL2, BCL6, or both (double-hit or triple-hit lymphoma), diffuse large B-cell lymphoma...objective response was achieved by 186 (73%, 95% CI 66·8–78·0) patients and a complete response by 136 (53%, 46·8–59·4)...
DOI:
10.1016/S0140-6736(20)31366-0
